Clinical Trials on Alzheimer’s Disease Conference (CTAD)
Clario is proud to be a silver sponsor of the 15th annual Clinical Trials on Alzheimer’s Disease conference (CTAD). CTAD is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease.
Schedule a meeting with the Clario team onsite, or visit our virtual booth during the conference to find out more.
Session 1 Information:
Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARIOT-PRO Substudy
Date: Wednesday, November 30th, 2022
Time: 2:40 p.m. PST
Authors: Gerald Novak, Ziad Saad, David Scott, Chi Udeh-Momoh, Luc Bracoud, Craig Ritchie, Lefkos Middleton
Session 2 Information:
Summary of ACR Phantom MRI site qualification findings over 7 years and recommendations moving forward
Date: Thursday, December 1st, 2022
Poster Session: P077
Time: 8:00 a.m. – 6:00 p.m. PST
Authors: Luc Bracoud, Joonmi Oh, Qui Cao, Chris Conklin, Madhura Ingalhalikar, Ha Pham, David Scott, Joyce Suhy
Session 3 Information:
Prevalence of microhemorrhages, superficial siderosis and other MRI abnormalities in a population of cognitively unimpaired older adults from the CHARIOT-PRO study
Date: Thursday, December 1st, 2022
Poster Session: LP59
Time: 8:00 a.m. – 6:00 p.m. PST
Authors: Luc Bracoud , Chi Udeh-Momoh, Ziad Saad, Dimitra Kafetsouli, Emmett Daly, Onah Okoye, Parthenia Giannakopoulou, David Scott, Joyce Suhy, Susan Baker, Gerald Novak, Craig Ritchie, Lefkos Middleton
Featured presenters:
David Scott, PhD
VP, Medical & Scientific Affairs, Neuroscience at Clario
David Scott, Ph.D., is Vice President, Medical and Scientific Affairs at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction.
Since joining Clario in 2012, David’s focus has been to enable MRI and molecular imaging solutions toward safety, eligibility, and therapeutic efficacy endpoints. He works with radiologists, physicists, software engineers, and operational specialists on the design, execution, analysis, and interpretation of neuroscience clinical trial imaging data. His motivation is to enable neuroimaging to accelerate the delivery of therapeutic benefit to patients around the world.
Luc Bracoud, MSc
Director, Neuroscience at Clario
Luc Bracoud received his Master of Science degree from Ecole Centrale Lyon in 2001. He joined Clario in 2002 as a Project Manager and Research and Development Engineer where he developed various brain MRI image-processing algorithms including image registration, segmentation, DTI, PWI and brain atrophy assessment, and managed large Alzheimer’s disease (AD), Multiple Sclerosis (MS) and Stroke clinical trials. Luc then transitioned to an oversight role where he designs and directs all of Clario’s MRI Neuroscience trials, from a scientific and technical perspective.
Joyce Suhy, PhD
Senior VP, Medical Imaging at Clario
Working in the field of Medical Imaging since 1992, Dr. Suhy has authored numerous journal articles and book chapters in imaging of the brain. Dr. Suhy has lead the design and scientific oversight of Neuroscience clinical trials since 2001, within the following indications: Alzheimer’s disease (AD), Mild Cognitive Impairment, Prodromal AD, Dementia with Lewy Body, Vascular Dementia, Frontotemporal Dementia, Down Syndrome, Huntington’s Disease, Multiple Sclerosis, Parkinson’s disease, Progressive Supranuclear Palsy, Trauma, Brain Tumors, Stroke and Stroke Devices, Intracranial Hemorrhage, Post-Traumatic Stress Disorder, Spinal Cord Injury, CADASIL, Fabry disease, Multiple System Atrophy, Contrast Agents, Pediatric indications, Rare diseases, etc. Dr. Suhy has also participated on several expert panels to advance the use of imaging in clinical trials.